Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

GMED or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jun 5, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Diamond Hill Long-Short Strategy Q1 2026 Portfolio Movers: Gains, Drags, And Trades

Diamond Hill's long positions in software businesses, including Microsoft , Salesforce and Adobe, were among the most notable detractors in the quarter. Exploration and production companies Chevron and Diamondback Energy saw shares rise as the sharp increase in oil prices drove a broad rally across US-based oil producers. Diamond Hill initiated a position in Gartner as concerns around slowing revenue growth and potential disruption from AI created an opportunity to invest at an attractive valuation.

Seeking Alpha • May 19, 2026

Artisan Small Cap Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.

Seeking Alpha • May 7, 2026

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.

Zacks Investment Research • May 6, 2026

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

PRNewsWire • May 6, 2026

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • May 5, 2026

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Apr 27, 2026

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

Seeking Alpha • Apr 27, 2026